Patent Issued for Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 (USPTO 11919956).

A patent has been issued for heterodimeric antibodies that bind to prostate specific membrane antigen (PSMA) and CD3. These antibodies have the potential to treat prostate cancer by redirecting CD3+ T cells to destroy cancer cells. The patent describes the composition of the antibodies, including the variable heavy and light domains, and provides information on nucleic acid compositions, expression vectors, and host cells for producing these antibodies. The invention aims to provide additional anti-PSMA antibodies for the treatment of PSMA-related cancers, such as prostate cancer. [Extracted from the article]

Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)